About Embolx
Embolx is a company based in Sunnyvale (United States) founded in 2013. It operates as a Direct-to-Consumer (D2C) and HealthTech. Embolx has raised $500 thousand across 3 funding rounds from investors including HHS. Embolx offers products and services including Sniper Balloon Occlusion Microcatheter, Soldier High Flow Microcatheter, and Sniper G3 Balloon Occlusion Microcatheter. Embolx operates in a competitive market with competitors including Augmedics, TriSalus Life Sciences, Proprio, ClearPoint Neuro and IMRIS Deerfield Imaging, among others.
- Headquarter Sunnyvale, United States
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Embolx, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$500 K (USD)
in 3 rounds
-
Latest Funding Round
$1.86 M (USD), Grant
Sep 25, 2015
- Investors
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Embolx
Embolx offers a comprehensive portfolio of products and services, including Sniper Balloon Occlusion Microcatheter, Soldier High Flow Microcatheter, and Sniper G3 Balloon Occlusion Microcatheter.
Used for targeted arterial embolization in medical procedures.
Designed for high-flow delivery in embolization treatments.
Enhanced microcatheter for efficient and targeted embolization.
People of Embolx
Unlock access to complete
Unlock access to complete
Funding Insights of Embolx
Embolx has successfully raised a total of $500K across 3 strategic funding rounds. The most recent funding activity was a Grant round of $1.86 million completed in September 2015. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Embolx
Embolx has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Public health and human services are overseen by HHS.
|
Locked | Locked | Locked |
Investor details for Embolx
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Embolx
Investment portfolio details for Embolx
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Embolx
Detailed financials for Embolx
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Embolx Comparisons
Peer comparison for Embolx
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Embolx
Embolx operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Augmedics, TriSalus Life Sciences, Proprio, ClearPoint Neuro and IMRIS Deerfield Imaging, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Augmented reality systems for guiding surgical procedures are developed.
|
|
| Locked | Locked | Locked |
Developer of drug delivery devices to treat cancers
|
|
| Locked | Locked | Locked |
Visualization systems for surgical procedures are developed using machine learning.
|
|
| Locked | Locked | Locked |
Software and hardware solutions for MRI-guided surgical planning are provided.
|
|
| Locked | Locked | Locked |
Surgical theatres with ceiling mounted mobile imaging devices to enhance intraoperative workflow
|
|
| Locked | Locked | Locked |
Robotic surgery platform for bone procedures is developed.
|
Detailed competitors of Embolx
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Embolx
Complete news archive for Embolx
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Embolx
Embolx was founded in 2013 and raised its 1st funding round 1 year after it was founded.
Embolx is headquartered in Sunnyvale, United States. It is registered at Sunnyvale, California, United States.
Embolx is a funded company, having raised a total of $500K across 3 funding rounds to date.
Embolx is engaged in the development and innovation of microcatheters for arterial embolization procedures. Solutions are provided for targeted medical interventions using high-pressure and low-pressure techniques. The healthcare sector, specifically interventional radiology, is served through products like the Sniper Balloon Occlusion Microcatheter and Soldier High Flow Microcatheter. Advancements are continuously made, as seen with the release of the Sniper G3, enhancing efficiency and usability in medical treatments.
Embolx's top competitors include Augmedics, Proprio and TriSalus Life Sciences.
Embolx offers Sniper Balloon Occlusion Microcatheter, Soldier High Flow Microcatheter, and Sniper G3 Balloon Occlusion Microcatheter.
Embolx has 1 investor. Key investors include HHS.